When CATB in the brain of AD mice was depleted genetically or inhibited pharmacologically by administration of cysteine protease inhibitor E64d, the amyloid deposition and cognitive decline were delayed, suggesting that the enzyme may become a potential drug target for AD [34,36,43,66,67,68]. This evidence concerns the gene TYRP1 and Alzheimer disease.